<DOC>
	<DOC>NCT02871258</DOC>
	<brief_summary>To study objective is to evaluate the impact of use of The MetaNeb® System in clearance of atelectasis, as demonstrated by improvement in chest x-rays. This is a a non-randomized open label study, with all subjects receiving treatment with The MetaNeb® System. Subjects who qualify for enrollment in the study will receive therapy with The MetaNeb® System following the labeled instructions for the device. Details of the treatment including duration and frequency will be defined in treatment procedures.</brief_summary>
	<brief_title>MetaNeb® Chest X-ray Study</brief_title>
	<detailed_description>Study Population: Post-surgical (thoracic, cardiac or abdominal surgery) non-mechanically ventilated patients with significant atelectasis as documented by chest x-ray results. Duration of treatment: Duration of treatment with The MetaNeb® System will be a minimum of 48 hours, or until the subject is discharged from the hospital (if discharge is earlier). Enrolled subjects will remain in the study through Day 4 or until the subject is discharged from the hospital, whichever occurs sooner.</detailed_description>
	<mesh_term>Pulmonary Atelectasis</mesh_term>
	<criteria>Postsurgical (thoracic, cardiac or abdominal surgery) Age ≥ 18 years Significant atelectasis by chest xray Patient meets indication for therapy intervention as defined by Recruitment and Airway Clearance Protocol (Respiratory Department Policy and Procedure) Signed informed consent Cause of atelectasis suspected to be infectious or solid mass Requirement for mechanical ventilation Requirement for chronic supplemental oxygen Hemodynamically unstable, as defined by need for vasopressor therapy Anticipated need for mechanical ventilation or other poor clinical outcome, unrelated to atelectasis or secretion retention Contraindication to MetaNeb® therapy (untreated tension pneumothorax) Inability to perform MetaNeb® therapy using a mouthpiece Anticipated hospital discharge within 24 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>